Патогенез ВИЧ-инфекции: 25 лет открытий и загадок ... - Tb-hiv.ru

Ïàòîãåíåç ÂÈ×-èíôåêöèè: 25 ëåò îòêðûòèé è çàãàäîê11194. Chiu YL, Soros VB, Kreisberg JF, et al. Cellular APOBEC3G restrictsHIV-1 infection in resting CD4R T cells. Nature 2005; 435:108–114.95. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic bodycomponent TRIM5 restricts HIV-1 infection in old world monkeys.Nature 2004; 427:848–853.96. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release andis antagonized by HIV-1 Vpu. Nature 2008; 451:425–430.97. Varthakavi V, Heimann-Nichols E, Smith RM, et al. Identification ofcalcium-modulating cyclophilin ligand as a human host restriction toHIV-1 release overcome by Vpu. Nat Med 2008; 14:641–647.98. Fellay J, Shianna KV, Ge D, et al. A whole-genome associationstudy of major determinants for host control of HIV-1. Science 2007;317:944–947.99. Konig R, Zhou Y, Elleder C, et al. Global analysis of host-pathogeninteractions that regulate early-stage HIV-1 replication. Cell 2008;135:49–60.100. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of hostproteins required for HIV infection through a functional genomicscreen. Science 2008; 319:921–926.101. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innateimmunity. Cell 2006; 124:783–801.102. Fust G, Ujhelyi E, Hidvegi T, et al. The complement system in HIVdisease. Immunol Invest 1991; 20:231–241.103. Hart ML, Saifuddin M, Uemura K, et al. High mannose glycans andsiliac acid on gp120 regulate binding of mannose-binding lectin(MBL) to HIV type 1. AIDS Res Hum Retroviruses 2002; 18:1311–1317.104. Wada M, Wada NA, Shirono H, et al. Amino-terminal fragment ofurokinase-type plasminogen activator inhibits HIV-1 replication.Biochem Biophys Res Commun 2001; 284:346–351.105. Munch J, Standker L, Adermann K, et al. Discovery and optimizationof a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.Cell 2007; 129:263–275.106. Rodman TC, Lutton JD, Jiang S, Al-Kouatly HB, Winston R. Circulatingnatural IgM antibodies and their corresponding human cordblood cell-derived Mabs specifically combat the Tat protein of HIV.Exp Hematol 2001; 29:1004–1009.107. Lobo PI, Schlegel KH, Yuan W, Townsend GC, White JA. Inhibitionof HIV-1 infectivity through an innate mechanism involving naturallyoccurring IgM antileukocyte autoantibodies. J Immunol 2008;180:1769–1779.108. Gomez MB, Hildreth JEK. Antibody to adhesion molecule LFA-1enhances plasma neutralization of human immunodeficiency virustype 1. J Virol 1995; 69:4628–4632.109. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to humanimmunodeficiency virus infectivity and sensitivity to neutralization.J Virol 1997; 71:4847–4851.110. Wang SK, Liang PH, Astronomo RD, et al. Targeting the carbohydrateson HIV-1: Interaction of oligomannose dendrons with humanmonoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A2008; 105:3690–3695.111. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clashof evolutionary titans. Proc Natl Acad Sci U S A 2005; 102:14943–14948.112. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptorinteractions in human immunodeficiency virus type 1 Env function:soluble CD4 activates Env for coreceptor-dependent fusion andreveals blocking activities of antibodies against cryptic conservedepitopes on gp120. J Virol 2000; 74:326–333.113. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservationand immunogenicity of the HIV coreceptor binding site. J Exp Med2005; 201:1407–1419.114. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation betweenantibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J ClinImmunol 2001; 21:227–233.115. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiencyvirus (HIV) correlates with disease in HIV infected individuals.J Virol 1990; 64:1437–1440.116. Morrow WJW, Isenberg DA, Sobol RE, Stricker RB, Kieber-EmmonsT. AIDS virus infection and autoimmunity: A perspective of the clinical,immunological, and molecular origins of the autoallergic pathologiesassociated with HIV disease. Clin Immunol Immunopathol1991; 58:163–180.117. Banchereau J, Steinman RM. Dendritic cells and the control of immunity.Nature 1998; 392:245–252.118. Donaghy H, Stebbing J, Petterson S. Antigen presentation and therole of dendritic cells in HIV. Curr Opin Infect Dis 2004; 17:1–6.119. Liu YJ. IPC: professional type 1 interferon-producing cells andplasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275–306.120. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principaltype 1 interferon-producing cells in human blood. Science 1999;284:1835–1837.121. Schmidt B, Scott I, Whitmore RG, et al. Low-level HIV infection ofplasmacytoid dendritic cells: onset of cytopathic effects and celldeath after PDC maturation. Virology 2004; 329:280–288.122. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating naturaltype 1 interferon-producing cells in HIV-infected AIDS patients.Blood 2001; 98:906–912.123. Killian MS, Fujimura S, Hecht FM, Levy JA. Similar changes in plasmacytoiddendritic cell and CD4R T cell counts during primary HIV-1 infection and treatment. AIDS 2006; 20:1247–1252.124. Malleret B, Maneglier B, Karlsson I, et al. Primary infection with simianimmunodeficiency virus: plasmacytoid dendritic cell homingto lymph nodes, type I IFN and immune suppression. Blood 2008.[Epub ahead of print].125. Kottilil S, Shin K, Planta M, et al. Expression of chemokine and inhibitoryreceptors on natural killer cells: effect of immune activationand HIV viremia. J Infect Dis 2004; 189:1193–1198.126. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B andKIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733–740.127. Godfrey DI, Kronenberg M. Going both ways: immune regulationvia CD1d-dependent NKT cells. J Clin Invest 2004; 114:1379–1388.128. Moser B, Brandes M. Gammadelta T cells: an alternative type of professionalAPC. Trends Immunol 2006; 27:112–118.129. Norris PJ, Moffett HF, Yang OO, et al. Beyond help: direct effectorfunctions of human immunodeficiency virus type 1-specific CD4R Tcells. J Virol 2004; 78:8844–8851.130. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentiallymaintain highly functional HIV-specific CD8R T-cells. Blood2006; 107:4781–4789.131. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4R T cell responses associated with control of viremia.Science 1997; 278:1447–1450.132. Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association betweenvirus-specific cytotoxic T-lymphocyte and helper responsesin human immunodeficiency virus type 1 infection. J Virol 1999;73:6715–6720.133. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibithepatitis B virus gene expression by a noncytolytic mechanismin transgenic mice. Proc Natl Acad Sci U S A 1994; 91:3764–3768.134. Khana KM, Lepisto AJ, Hendricks RL. Immunity to latent viral infection:many skirmishes but few fatalities. Trends Immunol 2004;25:230–234.135. Iversen AC, Norris PS, Ware CF, Benedict CA. Human NK cells inhibitcytomegalovirus replication through a noncytolytic mechanisminvolving lymphotoxin-dependent induction of IFN-beta. J Immunol2005; 175:7568–7574.136. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxicT lymphocytes and plasma load of viral RNA. Science 1998;279:2103–2106.